Researcher
Steven De Jonghe
- Disciplines:Microbiology, Systems biology, Laboratory medicine
Affiliations
- Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 May 2017 → Today - Medicinal Chemistry (Rega Institute) (Division)
Member
From18 Feb 2002 → 30 Apr 2017
Projects
1 - 10 of 18
- Synthesis of agonists for the C-C chemokine receptor type 5 (CCR5), derived from a substituted 4-aminopiperidinyl lead structureFrom1 Jan 2023 → TodayFunding: BOF - doctoral mandates
- Optimisation of a triterpene lead compound for the development of pan-anticoronavirus drugs targeting nsp15From3 Jan 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Synthesis and structure-activity relationship studies of CCR8 agonists as a novel treatment option for autoimmune diseasesFrom27 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The synthesis of novel CXCR4 antagonists for use in oncology and molecular imagingFrom1 Oct 2020 → 30 Sep 2021Funding: BOF - postdoctoral mandates
- An NMR facility tailored for biomedical researchFrom1 May 2020 → TodayFunding: FWO Medium Size Research Infrastructure
- Synthesis of nucleoside analogues as antiviral and antibacterial agentsFrom10 Feb 2020 → 10 Feb 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Development and application of NanoBRET-based technology: Unravelling signalling bias at the human chemokine receptors CXCR1 and CXCR2From3 Sep 2019 → 3 Sep 2023Funding: Own budget, for example: patrimony, inscription fees, gifts
- Synthesis of CXCR2 and CCR7 chemokine receptor antagonists targeting a conserved intracellular binding siteFrom3 Oct 2018 → 10 Jan 2023Funding: BOF - doctoral mandates
- Establishment of in vitro assays for the discovery of GPCR small molecule ligandsFrom30 May 2018 → 30 May 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- IN SEARCH FOR SUGAR, BASE OR PHOSPHATE MODIFIED NUCLEOSIDES ACTIVE AGAINST RNA VIRUSESFrom30 Nov 2017 → 7 Mar 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
21 - 30 of 129
- Azapeptide activity-based probes for the SARS-CoV-2 main protease enable visualization of inhibition in infected cells(2023)
Authors: Roeland Vanhoutte, Dirk Jochmans, Steven De Jonghe, Johan Neyts, Steven Verhelst
Pages: 1666 - 1672 - Visible-Light-Promoted Tandem Thiol-Ene Click Reaction/Transannular Cyclization and Regioselective Cyclopropane Ring- Opening to Construct Sulfur-Containing Euphorbia Diterpenes(2023)
Authors: Steven De Jonghe, Dominique Schols
- Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery(2023)
Authors: Kayvan Abbasi, Dirk Jochmans, Steven De Jonghe, Hendrik Jan Thibaut, Johan Neyts, Manon Laporte, Pieter Leyssen
- Synthesis, characterization, molecular docking, and anticancer activities of new 1,3,4-oxadiazole-5-fluorocytosine hybrid derivatives(2023)
Authors: Johan Neyts, Dirk Jochmans, Steven De Jonghe
- Synthesis of CXCR2 and CCR7 chemokine receptor antagonists targeting a conserved intracellular binding site(2023)
Authors: Max Van Hoof, Wim Dehaen, Steven De Jonghe
- Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors(2023)
Authors: Hongtao Xu, Merel Oeyen, Steven De Jonghe, Dirk Jochmans, Johan Neyts, Piet Herdewyn, Dominique Schols
- Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters(2022)
Authors: Rana Abdelnabi, Piet Maes, Steven De Jonghe, Birgit Weynand, Johan Neyts
- Synthesis and evaluation of 3-alkynyl-5-aryl-7-aza-indoles as broad-spectrum antiviral agents(2022)
Authors: Mirthe Graus, Emiel Vanhulle, Johan Neyts, Dominique Schols, Kurt Vermeire, Steven De Jonghe
- A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection(2022)
Authors: Rana Abdelnabi, Suzanne Kaptein, Robbert Boudewijns, Steven De Jonghe, Dirk Jochmans, Birgit Weynand, Johan Neyts
- Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategies(2022)
Authors: Steven De Jonghe
Patents
1 - 10 of 10
- Isoquinoline and pyridine based cxcr4 antagonists (Inventor)
- Prodrugs of nucleoside phosphonates (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Antiviral activity of bicyclic heterocycles (Inventor)
- Antiviral compounds, a process for their preparation, and their use for treating viral infections (Inventor)
- Prodrugs of fluorinated acyclic nucleoside phosphonates (Inventor)
- Purine analogues and their use as immunosuppressive agents (Inventor)
- Novel prodrugs of nucleoside phosphonates (Inventor)
- Gak modulators as antivirals (Inventor)